29 results about "Inhalant Solution" patented technology

The invention relates to a nintedanib dry powder inhalant as well as a preparation method and application thereof. The dry powder inhalant comprises nintedanib and magnesium stearate. According to the nintedanib dry powder inhalant, by controlling the adding proportion of magnesium stearate and the particle size distribution of co-micro powder, the dosage of fine particles can be remarkably increased, the nintedanib dry powder inhalant still has the high dosage of fine particles under the high drug loading capacity, the drug bioavailability is high, and the safety risk of a patient in the medication period can be reduced. Meanwhile, the preparation method of the nintedanib dry powder inhalant is simple and controllable, and the final product is safe, reliable and high in stability.

The invention discloses an application of a synephrine dry powder inhalant in preparation of a medicine for treating acute lung injury. According to the invention, the synephrine is prepared into a dry powder inhaler (DPI) dosage form, so that the problem of low bioavailability of the synephrine is overcome, and the synephrine is directly and actively targeted to the lung after being administered to the lung, so that the plasma concentration of the lung is increased, and the distribution of the medicine in other tissues is reduced, thereby improving the curative effect of the medicine and reducing the side effects of the whole body. Meanwhile, the first-pass effect is avoided by a dry powder inhalation mode, so that the stability of the medicine is facilitated, and the treatment compliance of a patient is improved by a non-invasive administration way. The invention provides a new thought for the research of a pulmonary drug delivery system, and has a wide clinical application prospect.

The invention relates to a preparation method and application of a traditional Chinese medicine atomization inhalant for diffusing the lung and reducing phlegm, the preparation is prepared from eight medicinal materials including honey ephedra, bitter apricot kernel reformed, aster tataricus and the like through a staged extraction-multi-stage refining-composite stabilization integration process, volatile oil components are subjected to exclusive distillation concentration, non-volatile components are subjected to ethanol-water two-phase extraction, and then the volatile oil components are subjected to ethanol-water two-phase extraction to obtain the traditional Chinese medicine atomization inhalant for diffusing the lung and reducing phlegm. Chitosan flocculation is coupled with precise ultrafiltration to realize deep purification; molecular-level stabilization fusion of volatile oil and a refined water phase is innovatively realized through a composite surfactant system, and finally, a high-stability sterile solution meeting the requirement of an inhalant is prepared. The process overcomes the common problems that a compound traditional Chinese medicine atomized preparation is poor in clarity, effective components are easy to degrade and the atomization performance is poor, and it is ensured that the active components can be efficiently converted into lung targeted deposition superfine aerosol. The product is suitable for respiratory system diseases such as acute bronchitis, asthma turbid phlegm obstructing lung syndrome and the like, and has the advantages of quick response, high local drug concentration and good safety.

The invention belongs to the technical field of antioxidant drugs, and particularly relates to application of a glutathione dry powder inhaler in preparation of drugs for treating radiation acute lung injury, the glutathione dry powder inhaler comprises the following active ingredients by mass percentage: 50%-60% of reduced glutathione, 10%-20% of a carrier and 20%-30% of a dispersant, totaling 100%, the carrier is mannitol, and the dispersing agent is L-leucine. According to the invention, the glutathione dry powder inhalant accurately delivers high-concentration GSH to an alveolar injury area through a lung targeting delivery system, synchronously activates endogenous antioxidant enzymes, inhibits lipid peroxidation and an inflammation source, and blocks release of proinflammatory factors, so that radiation-induced oxidation-inflammation cascade reaction is directly inhibited, alveolar structure damage is relieved, and the anti-inflammatory effect is achieved. And an efficient new treatment strategy is provided for RILI.

The present application relates to a kind of biomimetic lung surfactant carrier, which is prepared from total fat and simulation peptide, in the total fat, the mass ratio of dipalmitoyl phosphatidylcholine, dipalmitoyl phosphatidylglycerol, dipalmitoyl phosphatidyl ethanolamine-polyethylene glycol 2000, cholesterol is 8-12:1:1:1;The lung surfactant simulation peptide is the simulation peptide of SP-B protein and / or the simulation peptide of SP-C protein.The biomimetic lung surfactant carrier has the advantages of high loading rate and high stability.The present application also relates to inhalation dosage form of drug for treating pulmonary arterial hypertension loaded by the biomimetic lung surfactant carrier, which makes the loaded drug obtain more uniform intra-pulmonary distribution, the inhalation drug is more close to natural lung surfactant in composition and physiological function, can delay the degradation of product, improve the utilization rate of drug, achieve good pulmonary arterial hypertension treatment effect.

The invention relates to the field of pharmacy, and particularly provides a method for treating cerebral apoplexy by using fluvoxamine. The invention proves that the fluvoxamine can be used for treating cerebral arterial thrombosis and has multiple effects. The invention also discloses an inhalant for treating cerebral arterial thrombosis. The inhalant comprises an effective amount of fluvoxamine.

The invention discloses a cationic immune liposome dry powder inhaler as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The cationic immune liposome dry powder inhaler disclosed by the invention is prepared from siRNA (small interfering Ribonucleic Acid) used for KRAS mutation, (2, 3-dioleyloxypropyl)-trimethyl ammonium chloride, dipalmitic acid phosphatidylcholine, cholesterol, 1, 2-distearoyl-SN-glycerol-3-phosphorylethanolamine-N-maleimide-polyethylene glycol 2000, palbolizumab and a freeze-drying protective agent. The composition is prepared through a freeze-drying process. The preparation method of the dry powder inhaler comprises the following steps: preparing the cationic liposome carrying the siRNA, preparing the cationic immune liposome coupled with the antibody, and freeze-drying the dry powder inhaler. Compared with a traditional administration mode, the inhalant has the advantages of being simple in preparation process, good in drug stability, high in targeting performance, obvious in-vivo distribution advantage and the like, and a new strategy is provided for treatment of the non-small cell lung cancer.

The invention provides a polypeptide coupling medicine and application thereof. The polypeptide coupling medicine comprises antiviral polypeptide, connecting polypeptide, amino acid and ambroxol which are connected in sequence. The polypeptide coupling drug provided by the invention is obtained by coupling a coronavirus membrane fusion inhibitor and ambroxol, and is formed by coupling polypeptide serving as a targeting carrier and a load drug through a connexon via a covalent bond. Through polypeptide coupled drug activity evaluation and pharmacokinetic research, evaluation of activity changes of polypeptide and ambroxol and research on drug exposure and half-life periods of inhalants and injections, the polypeptide coupled drug retains antiviral activity of polypeptide and phlegm eliminating / respiratory tract regulating functions of ambroxol, the drug exposure is increased, and the half-life period is prolonged.

The invention discloses a lipid composition containing saccharides or derivatives thereof and application of the lipid composition in enhancing nucleic acid transfection and disease treatment. The composition comprises (a) an active agent or a therapeutic agent containing nucleic acid; (b) a saccharide or a derivative thereof added in an amount of about 0.5-60 wt% of the total weight of the composition; (c) a cationic lipid; (d) a non-cationic lipid; and (e) a lipid conjugate. The composition can significantly improve the biological effect of the nucleic acid therapeutic agent and improve the biological effect of the nucleic acid therapeutic agent for treating or preventing diseases. The pharmaceutical composition can be applied to prevention or treatment of immune system diseases, cancers, virus infection, bacterial infection, metabolic diseases or hereditary diseases and the like, and the dosage forms comprise inhalant, nasal spray, freeze-dried powder, injection or solution.

The present invention discloses a composition for upper respiratory tract administration, which is used for the treatment and protection of fire injuries and contains a cyanide antidote and a metal chelating agent; with the appropriate carrier combination, the composition can be administered to the required individual in the form of a spray, an inhalant or a drop, etc. to prevent or treat the injuries caused by harmful substances at the fire scene.

The application relates to the technical field of pharmaceutical preparations, and discloses an agomelatine inhalant as well as a preparation method and application thereof. The agomelatine inhalant provided by the application comprises agomelatine or a pharmaceutically acceptable salt thereof in a form capable of being inhaled or capable of being changed into a form capable of being inhaled after being excited. From the aspect of synergism, the inhalant can avoid first-pass metabolism by changing a drug administration route, significantly improve bioavailability, and realize rapid effect by directly entering blood from the lung; from the aspect of attenuation, the inhalant can greatly reduce a drug usage amount to achieve a same treatment effect as a tablet, significantly reduce occurrence of drug toxic and side reactions, and significantly reduce liver toxicity by avoiding liver metabolism.

The invention belongs to the technical field of antioxidant drugs, and particularly relates to a glutathione dry powder inhalant as well as a preparation method and application thereof. The glutathione dry powder inhalant is prepared from the following active ingredients in percentage by mass: 50%-60% of reduced glutathione, 10%-20% of a carrier and 20%-30% of a dispersing agent, totaling 100%, the carrier is mannitol, lactose or trehalose, the dispersing agent is leucine, and no other pharmaceutic adjuvants exist. The glutathione dry powder inhalant is obtained by uniformly mixing the raw materials of the glutathione dry powder inhalant and then carrying out spray drying.

Provided is a ventilator that includes a breathing system, a mechanical system coupled to breathing system, and a control system coupled to breathing system and mechanical system. The control system includes pressure sensors, processing circuitry, and memory configured to store a look-up table. The processing circuitry receives a set of values for plurality of parameters, identifies a compression value from a plurality of compression values in the look-up table based on the received set of values. The processing circuitry causes the mechanical system to compress a bag valve of the breathing system in accordance with the identified compression value. The compression of the bag valve causes a gaseous inhalant to flow through the breathing system within a time-interval. The processing circuitry determines an actual volume of the gaseous inhalant and iteratively modifies the compression value of the bag valve to match a desired volume of the gaseous inhalant.

The utility model relates to a mint inhalant medicine core filling device. Comprising an inlet pipeline, a converging pipeline and an outlet pipeline which are arranged on a main body, the inlet pipeline and the outlet pipeline are converged on the converging pipeline, and a plurality of groups of to-be-mounted pipes are arranged in the inlet pipeline; the pipe loading assembly comprises a motor and a pipe loading component, the motor is arranged at the bottom of the main body, the output end of the motor is connected with the pipe loading component, and the pipe loading component is driven by the motor to push a to-be-loaded pipe entering the converging pipeline from the inlet pipeline into the inlet pipeline; the core installing assembly comprises a containing groove and a hydraulic component, the containing groove is connected to the main body, the to-be-installed cores are arranged in the containing groove in parallel, the hydraulic component is arranged outside the containing groove and connected with the pipe installing component, and the hydraulic component is driven by the motor to push the to-be-installed cores into a to-be-installed pipe of the pipeline. According to the utility model, the to-be-loaded pipe enters the inlet pipeline in a transverse state, and the to-be-loaded cores are pushed into the to-be-loaded pipe one by one in the process that the to-be-loaded pipe is pushed upwards and discharged step by step through the pipe loading component, so that continuous and efficient production is realized.

The invention provides an inhalant which comprises a PDE4 inhibitor, pharmaceutically acceptable auxiliary materials, a pH regulator and water, and the content of the PDE4 inhibitor accounts for 0.08%-0.1% of that of the inhalant. The inhalant has a good anti-inflammatory effect, the solubility of the medicine can be improved, the medicine loading capacity of the preparation is increased, the variety of auxiliary materials is few, and the interaction between the auxiliary materials and the medicine is reduced.

The invention discloses a dual-modular targeted delivery system and application of the dual-modular targeted delivery system in targeted anti-inflammatory drugs. The dual-modular targeted delivery system comprises an intravenous injection module and a respiratory tract inhalation module, the intravenous injection module is mesenchymal stem cells a-MSCs functionally modified by a first click chemical reaction group, and the respiratory tract inhalation module is drug-loaded nanoparticles b-NPs functionally modified by a second click chemical reaction group; according to the dual-modular targeted delivery system, the drug removal barrier is broken through through conjugate immune camouflage, the alveolar residence time of nanoparticles is prolonged, the drug concentration of a pneumonia focus area is increased, and the treatment effective rate is increased; due to the modular design, the whole-body exposure of NPs is reduced, and the liver and kidney toxicity is reduced; the single-time inhalation dosage is reduced, the patient compliance is improved, and the application prospect is great.

The invention belongs to the field of pharmaceutical preparations, and discloses a long-acting dry powder microsphere inhalant as well as a preparation method and application thereof. The inhalant is a long-acting dry powder microsphere inhalant prepared by taking a mixture of multi-cystic vesicles prepared from phospholipid and a dry powder auxiliary material as a drug carrier and entrapping active ingredients for treating lung diseases through a spray drying technology. Compared with a dry powder microsphere inhalant prepared from traditional monocystic lipidosome, the long-acting dry powder microsphere inhalant has a longer-time slow-release effect. According to the preparation, a unique process of firstly preparing multi-capsule vesicles and then performing spray drying is adopted, the obtained microspheres have an aerodynamic particle size of 1-5 microns, can be effectively deposited in the lung and show a remarkable long-acting slow-release characteristic, and the cumulative release rate reaches about 64% after 48-hour in-vitro release. Compared with a traditional monocystic liposome inhalant, the drug action time is effectively prolonged, the administration frequency is reduced, and the patient compliance is improved. The invention provides a new thought for the research of a pulmonary drug delivery system, and has a wide clinical application prospect.

The invention discloses an exercise physiological monitoring and intelligent dosing integrated protector device which comprises a chest fixing band and a shoulder fixing band. The shoulder fixing band is movably installed on one side of the chest fixing band, a containing disc is fixedly arranged in the middle of the chest fixing band, and sensors used for monitoring breathing, heart rate and blood oxygen of a user are arranged at the rear end of the containing disc; by means of the multiple sensors, the physiological indexes of a user during exercise can be monitored, the conditions of breathing, heart rate, blood oxygen and the like of the user are monitored, and different physiological indexes are monitored, so that whether the user is about to have the illness condition or not is judged, and the early warning function can be achieved; meanwhile, the nasal cavity spray head used for aerosol inhalation is wound on the containing disc, and the inhalant can be supplied to the asthma patient for inhalation through the nasal cavity spray head.

The present invention relates to an inhalation composition comprising a GLP-1 analogue and a transport carrier. The inhalation composition has high stability due to containing a small amount of impurities while having a high effective particle delivery capacity relative to the content of the composition, and has excellent flowability and fillability. In addition, the inhalation composition according to the present invention has high bioavailability compared to oral preparations due to delivering peptides directly to the lungs, and thus can reduce manufacturing costs by reducing the required dosage compared to oral preparations.

The invention provides naringin dry powder inhalation as well as a preparation method and application thereof, belongs to the technical field of pharmaceutical preparations, and particularly provides the naringin dry powder inhalation which comprises the following components in parts by mass: 1-30 parts of micronized naringin and 40-100 parts of a diluent, and the particle size distribution D90 of the micronized naringin is 1-30 [mu] m. The naringin dry powder inhalation provided by the invention is an inhalation administration preparation, has the advantages of high drug absorption rate and quick response, and the naringin dry powder inhalation provided by the invention has extremely low bitter taste and good patient compliance, and can be used for preparing an anti-inflammatory drug inhalant and / or a lung disease treatment drug.

The invention discloses a dry powder inhaler and a preparation method and application thereof, and relates to the technical field of biological medicine, the dry powder inhaler comprises an active component, a stabilizer, a cross-linking agent and an anti-sticking agent, the active component is fibroblast growth factor-10 (FGF-10); the stabilizing agent is a mixture of phospholipids and saccharides or sugar alcohols, and the phospholipids stabilizing agent is dipalmitoyl phosphatidylcholine (DPPC). According to the dry powder inhaler and the preparation method and application thereof, a three-dimensional network is formed through Ca / Mg / Zn and DPPC, a three-level pore structure (tap density is smaller than or equal to 0.18 g / cm) is constructed, the pulmonary alveolar deposition rate is increased to 72% or above, the stability of a particle framework is enhanced through the cross-linking mode, the physical stability of an FGF-10 dry powder inhaler is effectively improved, and the FGF-10 dry powder inhaler is suitable for being used for preparing the FGF-10 dry powder inhaler. The deposition efficiency of the medicine in the pulmonary alveoli is improved, and a better medicine delivery mode is provided for treating the smoke inhalation type lung injury.

The present invention relates to an inhalation composition comprising a GLP-1 analogue and a transport carrier. The inhalation composition has content stability and thermal stability while having a high effective particle delivery amount relative to content. In addition, the inhalable composition of the present invention directly delivers the peptide to the lungs, and thus has a bioavailability higher than that of oral agents. Therefore, manufacturing costs can be lowered through a reduction in required administration amount compared to that of oral agents.

The present invention discloses the use of synephrine dry powder inhalant in the preparation of a medicament for treating acute lung injury. By formulating synephrine into a dry powder inhalant (DPI) dosage form, the present invention overcomes the problem of low bioavailability of synephrine. After pulmonary administration, it directly and actively targets the lungs, increases the blood drug concentration in the lungs, reduces the distribution of the drug in other tissues, thereby improving the drug efficacy and reducing systemic side effects. At the same time, the dry powder inhalation method avoids the first-pass effect and is beneficial to the stability of the drug, and the non-invasive administration route increases the compliance of patients during treatment. The present invention provides a new idea for the research of pulmonary drug delivery systems and has broad clinical application prospects.

Generating a printable inhalant solution may include selecting identifiers for one or more identified chemicals and creating, for each identified chemical, a chemical specification that includes at least a quantity of the chemical. The chemical specifications in the aggregate may include a chemical signature of the selected identified chemicals. Further, a printable solution may be mechanically printed onto a predetermined flammable base substrate.

This invention discloses a method for preparing a bumetanide nasal administration formulation and its application in the treatment of epilepsy, belonging to the field of pharmaceutical technology. The nasal administration formulation is a bumetanide nasal spray and / or a bumetanide dry powder inhaler. The drug is used for immediate administration intervention within 30 minutes after an epileptic seizure in non-medical settings, including at home, outdoors, or during transport. In this invention, the bumetanide nasal spray or dry powder inhaler does not require intravenous puncture or operation by professional medical personnel. Patients or their families can administer the drug directly through the nasal cavity within 30 minutes after an epileptic seizure at home, outdoors, or during transport, breaking through the dependence of traditional intravenous injection on medical settings and equipment, and buying valuable time for neuronal resuscitation.

A method for estimating an inhale dose when a drug is delivered to a person using an inhaler is disclosed. A predicted inhale dose (PID) of the drug is estimated based on at least one first-type parameter and at least one second-type parameter. The first-type parameter is related to a breath pattern of the person, and the second-type parameter is related to the inhaler.

A liquid propellant-free pharmaceutical preparation including treprostinil is provided. The pharmaceutical preparation can undergo a better nebulization effect in a soft mist inhaler than the existing treprostinil preparations. In addition, the active substance in the pharmaceutical preparation is stable during a storage period of 1 to 2 years or longer.

The invention relates to application of an RIPK2 inhibitor GSK2983559 in preparation of drugs for preventing, treating and / or relieving pulmonary fibrosis, a novel strategy with great potential is provided for development of novel anti-pulmonary fibrosis drugs, GSK2983559 is clear in chemical structure and good in stability, can be easily prepared into various dosage forms such as injections and aerosol inhalers, can be applied to whole-body administration and local treatment, and can be applied to preparation of drugs for preventing, treating and / or relieving pulmonary fibrosis. The method is suitable for pulmonary fibrosis patients at different stages, and has good clinical transformation prospects and industrialization feasibility.